ReviewJournal of clinical medicine2022
"No-Reflow" Phenomenon: A Contemporary Review.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06342141 (Empagliflozin for Reducing the Risk of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction), which is not on this map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Empagliflozin for Reducing the Risk of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
Who cites it
50 citing papers in PubMed.
- [Angiographic result with the use of adenosine before percutaneous coronary intervention in pharmacoinvasive therapy].Revista medica del Instituto Mexicano del Seguro Social · 2024Trial
- Comparison of the Effects of Nicorandil and Sodium Nitroprusside on the Progression of Microvascular Obstruction in the Myocardial Infarction Zone in Rats.Bulletin of experimental biology and medicine · 2026Article
- Human Endothelium-on-a-Chip: Development of a Microfluidic Model for Cell Viability Assessment Under Oxidative Injury.International journal of molecular sciences · 2026Article
- Impact of multiple stent implantation on periprocedural myocardial infarction in patients undergoing planned pci in a clinically stable setting: insights from a single-centre cohort study.BMC cardiovascular disorders · 2026Article
- Review
- Predictive value of frontal QRS-T angle for no-reflow phenomenon in patients with acute coronary syndrome.BMC cardiovascular disorders · 2026Article
- Article
- The Naples Prognostic Score May Predict No Reflow in Patients Undergoing Percutaneous Coronary Intervention for Saphenous Vein Graft Stenosis.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Platelet-derived growth factor-BB is a novel inflammatory biomarker of no-reflow in STEMI patients treated with primary PCI.Journal of thrombosis and thrombolysis · 2026Observational
- Admission EASIX Score Predicts Coronary No-Reflow and In-Hospital Mortality in STEMI Patients Undergoing Primary PCI.Journal of clinical medicine · 2026Article
- Predictive value of the NORPACS score for malignant ventricular arrhythmias in STEMI patients undergoing primary PCI.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Predictors of Impaired Reperfusion in ST-Elevation Myocardial Infarction Treated with Primary PCI: Preliminary Results from COMA.NET Project.Diagnostics (Basel, Switzerland) · 2026Article
- Pharmacological strategies for myocardial protection in cardiac surgery: current science and the emerging role of multi-omics and artificial intelligence.Frontiers in cardiovascular medicine · 2026Review
- Article
- No-Reflow During Coronary Interventions: A Narrative Review.Journal of clinical medicine · 2025Review
- Predictive Value of Atherogenic Index for No-Reflow in Patients Undergoing Coronary Intervention for Saphenous Vein Graft with Acute Coronary Syndrome.Arquivos brasileiros de cardiologia · 2025Article
- Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial.European heart journal open · 2025Article
- Novel insights into no-reflow post-PCI: The predictive value of coronary sinus hemodynamics.Global cardiology science & practice · 2025Article
- Neutrophil Percentage/Albumin Ratio as an Independent Predictor of the No-Reflow Phenomenon in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary percutaneous angioplasty (pPCI), represents the reperfusion strategy of choice for patients with STEMI according to current international guidelines of the European Society of Cardiology. Coronary no-reflow is characterized by angiographic evidence of slow or no anterograde epicardial flow, resulting in inadequate myocardial perfusion in the absence of evidence of mechanical vessel obstruction. No reflow (NR) is related to a functional and structural alteration of the coronary microcirculation and we can list four main pathophysiological mechanisms: distal atherothrombotic embolization, ischemic damage, reperfusion injury, and individual susceptibility to microvascular damage. This review will provide a contemporary overview of the pathogenesis, diagnosis, and treatment of NR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.